Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Payables (2017 - 2025)

Serina Therapeutics (SER) has disclosed Payables for 9 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Payables rose 159.54% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, up 159.54% year-over-year, with the annual reading at $1.9 million for FY2025, 159.54% up from the prior year.
  • Payables hit $1.9 million in Q4 2025 for Serina Therapeutics, down from $2.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $4.0 million in Q1 2024 to a low of $348000.0 in Q2 2022.
  • Historically, Payables has averaged $1.3 million across 5 years, with a median of $997500.0 in 2022.
  • Biggest five-year swings in Payables: skyrocketed 467.61% in 2024 and later tumbled 70.4% in 2025.
  • Year by year, Payables stood at $771000.0 in 2021, then soared by 34.11% to $1.0 million in 2022, then tumbled by 43.91% to $580000.0 in 2023, then grew by 28.28% to $744000.0 in 2024, then soared by 159.54% to $1.9 million in 2025.
  • Business Quant data shows Payables for SER at $1.9 million in Q4 2025, $2.7 million in Q3 2025, and $1.7 million in Q2 2025.